Fosravuconazole L-lysine ethanolate

SKU: orb1298586

Description

Fosravuconazole L-lysine ethanolate is a prodrug of the broad-spectrum antifungal ravuconazole. It is clinically approved in Japan for treating onychomycosis and is used in research to study antifungal efficacy in both in vitro and in vivo experimental models.

Research Area

Infectious Disease & Virology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 914361-45-8
• MW: 739.7
• Purity: 99.43% (May vary between batches)
• Formula: C₃₁H₄₀F₂N₇O₈PS
• SMILES: N#CC1=CC=C(C2=CSC([C@H](C)[C@@](OCOP(O)(O)=O)(C3=CC=C(F)C=C3F)CN4N=CN=C4)=N2)C=C1.CCO.N[C@H](C(O)=O)CCCCN
• Target: Parasite,Antifungal
• Solubility: DMSO:48 mg/mL (64.89 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (2.7 mM)

Bioactivity

• In Vivo:
  Fosravuconazole (E-1224; 10-50 mg/kg; oral administration; daily; for 20 days) suppresses parasitemia and prevents death in mice infected with the T. cruzi Y strain.
  Read more...
• In Vitro:
  Fosravuconazole exhibits potent in vitro antifungal activity against a broad spectrum of fungal species, including Candida, Aspergillus, and Trichophyton species .
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

E-1224 L-lysine Ethanolate, E-1224 L-lysine ethanolate, antifungal, candidiasis, BMS-379224 L-lysine ethanolate, BMS-379224 L-lysine Ethanolate, Fosravuconazole L lysine ethanolate, Fosravuconazole L-lysine, Fosravuconazole Llysine ethanolate, Fosravuconazole L-lysine Ethanolate, Fungal, Inhibitor, onychomycosis, Parasite, parasitemia, inhibit, Ravuconazole

Compound Identifiers

PubChem CID

112499965